X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ALEMBIC LTD with Cipla - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC LTD vs CIPLA - Comparison Results

ALEMBIC LTD    Change

Alembic Limited, in its 99 years of existence, has evolved from being a tincture manufacturer to one of the prominent indigenous pharma companies in India. It is among the top players in the macrolides (anti-infective) and anti-microbials (animal hea... More

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC LTD CIPLA ALEMBIC LTD/
CIPLA
 
P/E (TTM) x 122.8 44.6 275.6% View Chart
P/BV x 4.6 3.8 119.4% View Chart
Dividend Yield % 0.2 0.3 73.2%  

Financials

 ALEMBIC LTD   CIPLA
EQUITY SHARE DATA
    ALEMBIC LTD
Mar-16
CIPLA
Mar-17
ALEMBIC LTD/
CIPLA
5-Yr Chart
Click to enlarge
High Rs53622 8.5%   
Low Rs29458 6.4%   
Sales per share (Unadj.) Rs4.7181.9 2.6%  
Earnings per share (Unadj.) Rs8.812.9 68.2%  
Cash flow per share (Unadj.) Rs9.029.3 30.7%  
Dividends per share (Unadj.) Rs0.152.00 7.5%  
Dividend yield (eoy) %0.40.4 98.7%  
Book value per share (Unadj.) Rs27.7155.7 17.8%  
Shares outstanding (eoy) m267.03804.51 33.2%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x8.73.0 292.8%   
Avg P/E ratio x4.742.0 11.1%  
P/CF ratio (eoy) x4.618.4 24.7%  
Price / Book Value ratio x1.53.5 42.7%  
Dividend payout %1.715.5 11.0%   
Avg Mkt Cap Rs m10,962434,516 2.5%   
No. of employees `000NA23.0 0.0%   
Total wages/salary Rs m23826,338 0.9%   
Avg. sales/employee Rs ThNM6,349.1-  
Avg. wages/employee Rs ThNM1,143.0-  
Avg. net profit/employee Rs ThNM449.3-  
INCOME DATA
Net Sales Rs m1,260146,302 0.9%  
Other income Rs m2642,287 11.5%   
Total revenues Rs m1,524148,589 1.0%   
Gross profit Rs m8324,758 0.3%  
Depreciation Rs m6113,229 0.5%   
Interest Rs m01,594 0.0%   
Profit before tax Rs m28512,222 2.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m2,096-70 -2,998.9%   
Extraordinary Inc (Exp) Rs m-320-   
Tax Rs m61,798 0.3%   
Profit after tax Rs m2,34310,354 22.6%  
Gross profit margin %6.616.9 38.8%  
Effective tax rate %2.114.7 14.6%   
Net profit margin %185.97.1 2,626.6%  
BALANCE SHEET DATA
Current assets Rs m1,68987,370 1.9%   
Current liabilities Rs m48633,081 1.5%   
Net working cap to sales %95.437.1 257.1%  
Current ratio x3.52.6 131.5%  
Inventory Days Days21787 249.5%  
Debtors Days Days8162 130.1%  
Net fixed assets Rs m1,624111,567 1.5%   
Share capital Rs m5341,609 33.2%   
"Free" reserves Rs m5,960123,645 4.8%   
Net worth Rs m7,404125,254 5.9%   
Long term debt Rs m10436,454 0.3%   
Total assets Rs m8,010209,532 3.8%  
Interest coverage x950.78.7 10,967.2%   
Debt to equity ratio x00.3 4.8%  
Sales to assets ratio x0.20.7 22.5%   
Return on assets %29.35.7 513.0%  
Return on equity %31.68.3 382.8%  
Return on capital %31.38.5 368.1%  
Exports to sales %2.934.2 8.6%   
Imports to sales %28.98.3 346.0%   
Exports (fob) Rs m3750,050 0.1%   
Imports (cif) Rs m36412,203 3.0%   
Fx inflow Rs m3751,066 0.1%   
Fx outflow Rs m36517,678 2.1%   
Net fx Rs m-32833,388 -1.0%   
CASH FLOW
From Operations Rs m34623,824 1.5%  
From Investments Rs m-48-13,127 0.4%  
From Financial Activity Rs m-301-13,239 2.3%  
Net Cashflow Rs m-3-2,478 0.1%  

Share Holding

Indian Promoters % 64.0 16.0 400.0%  
Foreign collaborators % 0.0 20.8 -  
Indian inst/Mut Fund % 0.2 12.2 1.6%  
FIIs % 9.7 23.7 40.9%  
ADR/GDR % 0.0 1.1 -  
Free float % 26.1 26.2 99.6%  
Shareholders   54,701 161,166 33.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC LTD With:   GSK PHARMA  TTK HEALTHCARE  ORCHID PHARMA LTD  DIVIS LABORATORIES  J.B.CHEMICALS  

Compare ALEMBIC LTD With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Strong Finish to the Week; Metal & Pharma Stocks Gain(Closing)

Indian share markets finished the trading session on a strong note amid firm Asian markets after comments from a Federal Reserve official eased worries about faster rate hikes in US.

Related Views on News

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Cipla: Extraordinary Income Boosts Net Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

Proceeds from the sale of the South African animal business bolstered Cipla's net profits for the quarter.

Cipla: Operating Margins Improve (Quarterly Results Update - Detailed)

Mar 8, 2017

Cipla has announced its results for the December quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC LTD SHARE PRICE


Feb 23, 2018 (Close)

TRACK ALEMBIC LTD

  • Track your investment in ALEMBIC LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ALEMBIC LTD 5-YR ANALYSIS

COMPARE ALEMBIC LTD WITH

MARKET STATS